Detail akcie Orphan Synergy online

Business Summary: OSE Immunotherapeutics SA, formerly Orphan Synergy Europe Pharma SA, is a France-based company, engaged in clinical stage biotechnological sector. It develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The Company's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. It provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.
Financial Summary: BRIEF: For the six months ended 30 June 2025, Ose Immunotherapeutics SA revenues decreased 98% to EUR1.4M. Net loss totaled EUR15.1M vs. income of EUR57.2M. Revenues reflect Turnover decrease of 98% to EUR1.3M, of which Other operating income decrease of 100% to EUR34K. Net loss reflects the conduct of research and development on pharmaceutical pr segment loss totaling EUR15.8M vs. income of EUR63.3M.